KRSA
Korsana Biosciences Inc.
KRSA | NASDAQ
$31.30
+$1.16 (+3.85%)
Nov 2, 2026, 11:19 AM ET · Market open
Company Profile
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Key Executives
| Name | Position |
|---|---|
| Jonathan Violin | President, CEO, Secretary & Director |
| Regina Graul | Chief Executive Officer, President & Director |
| Mark Joseph Vignola | Chief Financial Officer |
| Rhonda Chicko | Chief Financial Officer |
| Gan Wei | Chief Technical Officer |
| Kyle Breidenstine | Senior Vice President of Finance & Treasurer |
| Madelyn Demsky Zeylikman | General Counsel |
| Matthew Leoni | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 15, 2026 | DEF 14A | Filing |
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 05, 2026 | PRE 14A | Filing |
| Sep 18, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 16, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 15, 2026 | SC 13D | Filing |
| Sep 11, 2026 | SC 13D | Filing |
| Sep 11, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 4 | Filing |
Korsana Biosciences Inc.
KRSA
| Country | United States |
| IPO Date | Sep 9, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Jonathan Violin |
Stock Details
| Ticker Symbol | KRSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001755237 |
| CUSIP Number | 23255M303 |
| ISIN Number | US23255M3034 |
| SIC Code | 2834 |
Recent News
- 2 months ago / globenewswire.comKorsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
Add to Watchlist
Select watchlists to add or remove KRSA